A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

NCT00126451 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Colorectal Cancer
Non-small-cell Lung Carcinoma

Interventions

DRUG: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)
DRUG: Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles

Sponsor

Merck Sharp & Dohme LLC